Teumer Yannick, Hilgarth Franziska, Katov Lyuboslav, Melnic Rima, Rottbauer Wolfgang, Bothner Carlo, Weinmann Karolina
Department of Cardiology, Ulm University Heart Center, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
J Clin Med. 2024 Apr 13;13(8):2262. doi: 10.3390/jcm13082262.
Pulmonary vein isolation (PVI) is a common therapeutic approach for symptomatic atrial fibrillation (AF). Among various techniques, cryo-balloon (CB) PVI is widely adopted, but, to date, established CB systems have had fixed balloon sizes. A novel size-adjustable CB, allowing balloon size adjustments during ablation, lacks sufficient data on optimal utilization in patient care. This study aims to systematically investigate this feature with a tailored ablation protocol. Our single-center prospective study included patients with paroxysmal or persistent atrial fibrillation undergoing first-time PVI with the size-adjustable CB from July 2023 to February 2024. Ablation was performed using the balloon size that provided better occlusion. The ablation protocol involved an initial occlusion test with the small balloon size (28 mm). If optimal occlusion (occlusion level 4) could not be achieved, an attempt with the larger balloon (31 mm) was initiated. Ablation was conducted using the balloon configuration that provided better occlusion of the pulmonary vein ostium. Our prospective study includes 50 patients (median age [interquartile range, IQR]: 72 [65; 79] years, 24 [48.0%] females, and 35 [70.0%] patients with paroxysmal AF). The median procedure duration (IQR) was 77 (65; 96) minutes, and the median fluoroscopy time (IQR) was 17.7 (12.5; 22.0) min. PVI was successfully accomplished in each treated pulmonary vein (PV), with 87.4% of PVs isolated during the first freeze. The large balloon configuration was used to isolate 16.8% of PVs. The utilization of the size-adjustable CB, combined with the presented tailored ablation workflow, appears to facilitate effective and efficient pulmonary vein isolation. The use of a larger balloon configuration appears beneficial in isolating a significant proportion of the PVs.
肺静脉隔离(PVI)是治疗有症状心房颤动(AF)的常用方法。在各种技术中,冷冻球囊(CB)肺静脉隔离术被广泛采用,但迄今为止,现有的CB系统球囊尺寸固定。一种新型的可调节尺寸CB,可在消融过程中调整球囊大小,但在患者护理中的最佳应用方面缺乏足够的数据。本研究旨在通过定制的消融方案系统地研究这一特性。我们的单中心前瞻性研究纳入了2023年7月至2024年2月期间首次使用可调节尺寸CB进行阵发性或持续性心房颤动肺静脉隔离的患者。使用能提供更好封堵效果的球囊尺寸进行消融。消融方案包括先用小尺寸球囊(28mm)进行初始封堵测试。如果无法实现最佳封堵(封堵级别4),则开始尝试使用更大尺寸的球囊(31mm)。使用能更好封堵肺静脉口的球囊配置进行消融。我们的前瞻性研究包括50例患者(中位年龄[四分位间距,IQR]:72[65;79]岁,24例[48.0%]为女性,35例[70.0%]为阵发性AF患者)。中位手术时间(IQR)为77(65;96)分钟,中位透视时间(IQR)为17.7(12.5;22.0)分钟。每个治疗的肺静脉(PV)均成功完成肺静脉隔离,87.4%的肺静脉在首次冷冻时被隔离。16.8%的肺静脉使用大尺寸球囊配置进行隔离。可调节尺寸CB的应用,结合所提出的定制消融流程,似乎有助于有效且高效地进行肺静脉隔离。使用更大尺寸的球囊配置似乎有利于隔离相当比例的肺静脉。